Dr. Reddy's Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market
May 06 2020 - 3:34AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, along with its subsidiaries together referred to as “Dr.
Reddy’s”) today announced the launch of Desmopressin Acetate
Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic
equivalent generic version of DDAVP (desmopressin acetate)
Injection , 4 mcg/mL, approved by the U.S. Food and Drug
Administration (USFDA).
The DDAVP (desmopressin acetate) Injection USP brand and generic
market had U.S. sales of approximately $20.9 million MAT for the
most recent twelve months ending in March 2020 according to IQVIA
Health*.
Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s
Laboratories, commented, “The launch of Desmopressin Injection
demonstrates a strong, growing collaboration with SunGen Pharma. We
look forward to future opportunities with this company.”
Isaac Liu, Ph.D., Co-CEO of SunGen, stated, "We are pleased to
be working with Dr. Reddy’s for this launch. The launch of
Desmopressin demonstrates our strong development capabilities. We
look forward to collaborating further to bring specialty
pharmaceutical drugs to the markets around the world."
Dr. Reddy’s Desmopressin Acetate Injection USP, 4 mcg/mL is
available in a carton of ten 1 mL single-dose ampules.
Please click here for full prescribing information.
DDAVP is a trademark owned or licensed by Ferring
Pharmaceuticals, Inc
*IQVIA Retail and Non-Retail MAT March 2020 RDY-0520-293
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
About SunGen Pharma LLC: SunGen Pharma, LLC is a
privately held specialty pharmaceutical company which develops,
contract manufactures, and sells pharmaceutical finished products.
SunGen specializes in the development of oral solid extended
release, topical and complex injectable products. SunGen has
business partnerships with many North American, European and
Asian-based generic pharmaceutical companies to develop,
manufacture, and sell several pharmaceutical products around the
world. To date, SunGen has secured eight ANDA approvals and has an
addition seven filed with the FDA.
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility of our industry
and the markets addressed by our, and our customers’, products and
services to economic downturns as a result of natural disasters,
epidemics, pandemics or other widespread illness, including
coronavirus (or COVID-19), and (vii) other risks and uncertainties
identified in our public filings with the Securities and Exchange
Commission, including those listed under the "Risk Factors" and
"Forward-Looking Statements" sections of our Annual Report on Form
20-F for the year ended March 31, 2019. The company assumes no
obligation to update any information contained herein.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200506005363/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (PH:
+91-40-49002135)
MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com
(PH: +91-40-49002446)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2023 to Sep 2024